Bristol-Myers Squibb's Blood Product Sales Boost Q1 2026 Profits and Growth

How did blood-related product sales contribute to BMS’s higher-than-expected Q1 2026 profit?

From the provided Q1 2026 earnings call excerpts, Bristol-Myers Squibb attributed its stronger quarterly financial performance primarily to revenue strength and product mix, especially within its growth portfolio, and specifically highlighted hematology/blood-related assets as key contributors to that portfolio’s growth. However, the excerpts do not provide a direct breakout of “blood-related product sales” versus other segments within profit (e.g., no explicit statement like “blood-related sales added X basis points to EPS”). So the contribution must be inferred from what management did quantify: growth portfolio sales growth and the specific blood/hematology products driving that growth.

1) Management tied stronger results to growth portfolio momentum (with hematology assets included)

BMS stated that in Q1 2026 it delivered “solid R&D, commercial and financial performance” while managing costs, and that total revenue was up ~1% year-over-year to ~$11.5 billion. It also said its growth portfolio revenue increased 9% year-over-year to $6.2 billion, which is where the hematology “blood-related” products reside in the product set management highlighted. ¹

Because gross margin and operating costs are discussed after the product revenue review, this matters: profitability improvement would naturally flow from higher gross profit created by stronger product revenue and product mix, assuming costs are controlled. BMS noted that gross margin declined 280 bps to 70.3%, “primarily driven by product mix,” which implies mix was a factor but not necessarily in the direction of reducing profits entirely. ² The excerpt does not quantify whether operating income or EPS beat expectations, but it does show that management viewed overall performance as strong and reaffirmed guidance based on Q1 trends. ³

2) Hematology/blood-related products were explicitly cited as contributors to growth portfolio sales

BMS singled out multiple “growth portfolio” products, including Reblozyl and Breyanzi, when describing products driving year-over-year growth. ⁴

In the product performance section:

• Reblozyl delivered 15% growth, with performance reflecting “solid uptake across first and second line MDS-associated anemia.” ²
• In cell therapy (hematology/lymphoma blood indications), Breyanzi revenue grew 53% in the quarter, supported by continued strong demand across approved indications in the U.S. and internationally. ²

These are the clearest “blood-related product” datapoints in the excerpts, and they support the mechanism:

• Higher sales (Reblozyl +15%, Breyanzi +53%) likely increased the revenue base within the growth portfolio. ²
• That stronger growth portfolio performance is consistent with management’s statement that growth portfolio revenue increased 9% to $6.2 billion in Q1. ¹
• A stronger revenue base generally supports higher profit, though the call also flags that gross margin fell due to mix. ²

3) Why this translated into “higher-than-expected quarterly profit” (the mechanism visible in the excerpts)

The excerpt set supports the following link between blood-related sales and higher quarterly profit—without overstating causality beyond what’s shown:

1. Blood-related product revenues grew strongly (Reblozyl +15%, Breyanzi +53%) in Q1. ²
2. Those hematology products are part of BMS’s growth portfolio, whose revenue rose 9% to $6.2 billion. ¹
3. Management reported an effective tax rate of 18.3% and diluted EPS of $1.58 for the quarter, which included a net charge of $0.03 per share related to in-process R&D and licensing income. ³
   • While the excerpts don’t say the “higher-than-expected profit” figure, the presence of reported EPS and its components indicates that profitability was affected by both operating results and specific charges. ³
4. Operating expenses (excluding in-process R&D) were $3.9 billion, “slightly above” the prior year quarter, with offsetting effects from productivity savings versus incremental investments. ²
   • This suggests that even with some cost pressure, the business was still managed in a way that allowed strong overall financial performance. ²

Net effect: The excerpts support that hematology/blood-related products contributed by driving growth within the growth portfolio, which helped underpin the quarter’s strong financial outcome (via higher revenue and controlled cost structure). ²¹ The company also warns that gross margin declined due to product mix, meaning the profit lift came despite some unfavorable mix/margin dynamics rather than purely because margins improved. ²

4) What the excerpts do not show (important for intellectual honesty)

• They do not quantify how much of Q1 profit beat (or “higher-than-expected profit”) is attributable specifically to “blood-related product sales.” ²¹³
• They do not provide a segment margin/operating income breakdown for hematology products versus the rest of the portfolio. ²¹
• They mention margin pressure from mix and give some cost commentary, but not an “EPS bridge” that isolates blood-related sales as the incremental driver. ²

Bottom line

Based on the provided Q1 2026 excerpts, BMS’s blood-related product contribution to its stronger quarterly profitability is best explained as follows:

• Reblozyl (+15%) and Breyanzi (+53%) delivered strong sales growth in Q1 2026. ²
• These are part of BMS’s 9% growth portfolio revenue increase to $6.2 billion, which management cited as a core driver of overall performance. ¹⁴
• While gross margin declined to 70.3% due to product mix, the company’s overall financial result (including EPS $1.58 with a specified $0.03/sh net charge) reflects that the revenue strength from these growth products and cost discipline still supported a strong quarter. ²³

So, blood-related products contributed mainly by supplying disproportionately strong revenue growth within the growth portfolio, which in turn supported reported profitability—even though margins were pressured by product mix. ²¹³